| NCT07152379 | Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs | NOT_YET_RECRUITING | PHASE2 | 2026-01-01 | 2028-01-01 | 2027-10-01 |
| NCT07155031 | Biotin-Acridine Red Cell Exchange Kinetics | NOT_YET_RECRUITING | PHASE2 | 2025-10-15 | 2026-12-15 | 2026-09-30 |
| NCT07015437 | A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 | NOT_YET_RECRUITING | PHASE2 | 2025-07-15 | 2026-10-15 | 2026-07-30 |
| NCT06697223 | A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated with the INTERCEPT Blood System for Platelets with LED Illuminator. | NOT_YET_RECRUITING | PHASE2 | 2025-01-31 | 2025-12 | 2025-10 |
| NCT04022889 | In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days | COMPLETED | PHASE2 | 2019-11-05 | 2021-04-17 | 2021-04-16 |
| NCT03459287 | Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients | COMPLETED | PHASE3 | 2018-12-05 | 2024-03-05 | 2023-12-04 |
| NCT03037164 | INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections | RECRUITING | PHASE3 | 2017-05-11 | 2026-01-30 | 2025-10-31 |
| NCT02653443 | A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study | TERMINATED | PHASE2 | 2015-12 | 2016-05 | 2016-05 |
| NCT02295501 | A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease | TERMINATED | PHASE1 | 2014-12 | 2020-12 | 2020-12 |
| NCT02310412 | A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma | COMPLETED | PHASE2 | 2014-12 | 2015-09 | 2015-05 |
| NCT01716923 | Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia | COMPLETED | PHASE3 | 2013-04 | 2014-10 | 2014-07 |
| NCT01740531 | Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion | COMPLETED | PHASE3 | 2012-12 | 2017-12-31 | 2017-12-21 |
| NCT01711346 | A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells | COMPLETED | PHASE2 | 2012-10 | 2014-11 | 2014-07 |
| NCT00261924 | Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days | COMPLETED | PHASE3 | 2005-10 | 2009-07 | 2009-07 |